Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders

BACKGROUND: B cells can contribute to immune-mediated disorders. Targeting CD20 has proved to be efficacious in several B cell-mediated immunopathologies, as illustrated by the use of rituximab, the first anti-CD20 monoclonal antibody (mAb). Following rituximab, second- and third-generation anti-CD2...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaegi, Celine, Wuest, Benjamin, Crowley, Catherine, Boyman, Onur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847774/
https://www.ncbi.nlm.nih.gov/pubmed/35185862
http://dx.doi.org/10.3389/fimmu.2021.788830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847774/
https://www.ncbi.nlm.nih.gov/pubmed/35185862
http://dx.doi.org/10.3389/fimmu.2021.788830

Ejemplares similares